Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

This study tests a combination of four drugs — venetoclax, cladribine, low-dose cytarabine, and azacitidine — in older or less-fit adults who have been newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer, and are not suitable for standard intensive chemotherapy. **You may be eligible if...** - You have been newly diagnosed with acute myeloid leukemia (AML) and have not yet received treatment for it (minor prior stabilizing treatments may be allowed) - You are 50 years of age or older, OR you are younger but cannot safely tolerate standard induction chemotherapy - Your liver, kidney, and organ function meet the required levels **You may NOT be eligible if...** - You have already received treatment for AML (beyond the minor exceptions listed) - You are under 50 and are a suitable candidate for standard induction chemotherapy - Your organ function is too impaired to safely receive the study drugs Talk to your doctor to see if this trial is right for you.